Company / SG&A Expense
ResMed SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$991.0M
FY2025
5-year range
$670.4M / $991.0M
FY2021-FY2025
Trend
+8.1%
vs FY2024
Sector context
#46 of 152
Health Care
What the data says
At $991M, ResMed's sg&a expense ranks #107 of 152 in the Health Care sector. SG&A Expense has increased for 4 consecutive years, from $670M in FY2021 to $991M in FY2025.
Based on SEC 10-K filings.
$991M in FY2025 with a 5-year CAGR of +7.9%.
Increased from $874M to $991M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +10.3%
- 5-Year CAGR
- +7.9%
- 10-Year CAGR
- -
Sector benchmark
#107 of 152 in Health CareTop 70% of 152This company $991.0M Sector average $182.7B
▼
-99.5% below sector average
Key checks
Key Insights
- ResMed's sg&a expense has grown for 4 consecutive years.
- 5-year CAGR of +7.9%, indicating consistent growth.
- In FY2025, sg&a expense increased 8.1% year-over-year.
- Ranks #46 out of 152 companies in the Health Care sector.
Company context
Key Data Points
- High Piotroski F-Score: 8/9 (strong financial health signals)
- Altman Z-Score 3.25 (safe zone, above 2.9 threshold)
- Strong profit margin: 27.2%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $991.0M | +8.1% |
| FY2024 | $917.1M | +4.9% |
| FY2023 | $874.0M | +18.5% |
| FY2022 | $737.5M | +10.0% |
| FY2021 | $670.4M | -0.9% |
| FY2020 | $676.7M | +4.9% |
| FY2019 | $645.0M | +7.4% |
| FY2018 | $600.4M | +8.4% |
| FY2017 | $554.0M | +13.5% |
| FY2016 | $488.1M | +2.0% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026